NASDAQ : AVBP
ArriVent BioPharma, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 13.75 USD (Nov 2, 2026, 12:52 PM EST) · Market cap 677.98M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 31.64M | 24.18M | 15.30M | 9.71M | 6.47M | 3.02M |
| Research & Development | 144.30M | 153.35M | 79.00M | 64.88M | 30.43M | 8.58M |
| Operating Expenses | 175.94M | 177.53M | 94.31M | 74.59M | 36.91M | 11.59M |
| Operating Income | -175.94M | -177.53M | -94.31M | -74.59M | -36.91M | -11.59M |
| Interest & Investment Income | 12.21M | 11.23M | 13.82M | 5.26M | ||
| EBT Excluding Unusual Items | -163.74M | -166.31M | -80.49M | -69.33M | -36.91M | -11.59M |
| Pretax Income | -164.21M | -166.31M | -80.49M | -69.33M | -36.91M | -68.81M |
| Net Income | -164.21M | -166.31M | -80.49M | -69.33M | -36.91M | -68.81M |
| Net Income to Common | -164.21M | -166.31M | -80.49M | -69.33M | -36.91M | -68.81M |
| Shares Outstanding (Basic) | 44.41M | 38.46M | 31.47M | 2.14M | 1.28M | 711.19K |
| Shares Outstanding (Diluted) | 44.41M | 38.46M | 31.47M | 2.14M | 1.28M | 711.19K |
| EPS (Basic) | -3.70 | -4.32 | -2.56 | -32.38 | -28.90 | -96.75 |
| EPS (Diluted) | -3.70 | -4.32 | -2.56 | -32.38 | -28.90 | -96.75 |
| EBIT | -175.94M | -177.53M | -94.31M | -74.59M | -36.91M | -11.59M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 154.68M | 45.54M | 74.29M | 150.39M | 163.37M | 37.28M |
| Short-Term Investments | 218.44M | 267.28M | 144.57M | |||
| Cash & Short-Term Investments | 373.12M | 312.82M | 218.86M | 150.39M | 163.37M | 37.28M |
| Other Receivables | 500.00K | 761.00K | 500.00K | 250.00K | ||
| Receivables | 500.00K | 761.00K | 500.00K | 250.00K | ||
| Prepaid Expenses | 1.15M | 186.00K | 407.00K | 368.00K | 333.00K | 29.00K |
| Other Current Assets | 19.91M | 19.89M | 7.21M | 8.45M | 18.42M | 5.39M |
| Total Current Assets | 394.17M | 332.90M | 226.98M | 159.97M | 182.62M | 42.95M |
| Property, Plant & Equipment | 370.00K | 13.00K | 154.00K | 291.00K | 139.00K | |
| Long-Term Investments | 47.68M | |||||
| Long-Term Deferred Charges | 41.00K | 69.00K | 2.73M | |||
| Other Long-Term Assets | 134.00K | 190.00K | 126.00K | 107.00K | 72.00K | 87.00K |
| Total Assets | 394.72M | 333.17M | 274.94M | 163.10M | 182.83M | 43.04M |
| Accounts Payable | 2.22M | 5.93M | 3.78M | 4.53M | 3.09M | 293.00K |
| Accrued Expenses | 25.31M | 20.00M | 13.33M | 6.95M | 5.14M | 1.52M |
| Current Portion of Leases | 318.00K | 14.00K | 162.00K | 140.00K | 128.00K | |
| Total Current Liabilities | 27.84M | 25.95M | 17.27M | 11.62M | 8.36M | 1.82M |
| Long-Term Leases | 33.00K | 14.00K | 177.00K | 11.00K | ||
| Total Liabilities | 27.88M | 25.95M | 17.29M | 11.80M | 8.37M | 1.82M |
| Common Stock | 5.00K | 4.00K | 3.00K | |||
| Additional Paid-In Capital | 864.96M | 711.85M | 496.19M | 4.65M | 3.40M | 2.96M |
| Retained Earnings | -497.85M | -404.64M | -238.33M | -157.84M | -88.51M | -51.61M |
| Comprehensive Income & Other | -267.00K | 14.00K | -211.00K | -2.00K | ||
| Total Common Equity | 366.84M | 307.22M | 257.65M | -153.19M | -85.11M | -48.64M |
| Shareholders' Equity | 366.84M | 307.22M | 257.65M | 151.30M | 174.46M | 41.22M |
| Total Liabilities & Equity | 394.72M | 333.17M | 274.94M | 163.10M | 182.83M | 43.04M |
| Total Debt | 351.00K | 14.00K | 176.00K | 317.00K | 139.00K | |
| Net Cash (Debt) | 372.77M | 312.81M | 218.69M | 150.07M | 163.23M | 37.28M |
| Net Cash Per Share | 8.39 | 8.13 | 6.95 | 70.10 | 127.82 | 52.42 |
| Filing Date Shares Outstanding | 49.31M | 44.20M | 34.02M | 33.49M | 31.96M | 711.19K |
| Total Common Shares Outstanding | 48.32M | 42.45M | 33.71M | 2.75M | 2.60M | 711.19K |
| Working Capital | 366.33M | 306.95M | 209.71M | 148.34M | 174.26M | 41.13M |
| Book Value Per Share | 7.59 | 7.24 | 7.64 | -55.80 | -32.76 | -68.40 |
| Tangible Book Value | 366.84M | 307.22M | 257.65M | -153.19M | -85.11M | -48.64M |
| Tangible Book Value Per Share | 7.59 | 7.24 | 7.64 | -55.80 | -32.76 | -68.40 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -164.21M | -166.31M | -80.49M | -69.33M | -36.91M | -68.81M |
| Asset Writedown & Restructuring Costs | 57.21M | |||||
| Stock-Based Compensation | 19.09M | 12.52M | 3.21M | 895.00K | 424.00K | 66.67K |
| Other Operating Activities | -3.62M | -3.03M | ||||
| Change in Accounts Payable | -1.84M | 2.14M | -751.00K | 1.38M | 2.80M | 390.67K |
| Change in Other Net Operating Assets | 2.66M | -5.92M | 7.82M | 11.22M | -9.95M | -5.65M |
| Operating Cash Flow | -147.93M | -160.59M | -70.21M | -55.84M | -43.63M | -16.78M |
| Sale (Purchase) of Intangibles | -53.33M | |||||
| Investment in Securities | -72.31M | -71.23M | -192.47M | |||
| Investing Cash Flow | -72.31M | -71.23M | -192.47M | -53.33M | ||
| Total Debt Issued | 266.67K | |||||
| Total Debt Repaid | -266.67K | |||||
| Issuance of Common Stock | 261.87M | 203.13M | 186.58M | 354.00K | 17.00K | 2.67K |
| Other Financing Activities | 283.00K | -70.00K | -2.41M | |||
| Financing Cash Flow | 262.15M | 203.06M | 186.58M | 42.86M | 169.72M | 119.82M |
| Net Cash Flow | 41.92M | -28.75M | -76.10M | -12.98M | 126.09M | 49.71M |
| Levered Free Cash Flow | -89.48M | -101.58M | -48.64M | -32.80M | -29.81M | |
| Unlevered Free Cash Flow | -89.48M | -101.58M | -48.64M | -32.80M | -29.81M | |
| Change in Working Capital | 818.00K | -3.77M | 7.07M | 12.60M | -7.15M | -5.25M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 673.05M | 830.58M | 897.69M | |||
| Enterprise Value | 300.28M | 530.37M | 615.05M | |||
| Last Close Price | 14.87 | 20.12 | 26.64 | |||
| PB Ratio | 1.96 | 2.70 | 3.48 | |||
| P/TBV Ratio | 2.00 | 2.70 | 3.48 | |||
| Debt / Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Debt / Equity Ratio | -1.02 | -1.02 | -0.85 | -0.99 | -0.94 | -0.90 |
| Quick Ratio | 13.40 | 12.06 | 12.70 | 13.00 | 19.60 | 20.64 |
| Current Ratio | 14.16 | 12.83 | 13.14 | 13.76 | 21.84 | 23.63 |
| Return on Equity (ROE) | -53.25% | -58.88% | -39.36% | -42.57% | -34.22% | |
| Return on Assets (ROA) | -33.11% | -36.49% | -26.91% | -26.95% | -20.42% | |
| Return on Capital Employed (ROCE) | -48.00% | -57.80% | -36.60% | -49.20% | -21.20% | -28.10% |
| Earnings Yield | -27.09% | -20.02% | -8.97% | |||
| Buyback Yield / Dilution | -30.39% | -22.22% | -1,369.88% | -67.64% | -79.57% |